Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial

This 19-week, double-blind, placebo-controlled, randomized phase 2 study evaluated the efficacy, safety, and tolerability of adjunctive cariprazine (0.1–0.3 and 1.0–2.0 mg/day) as an antidepressant treatment for adults with treatment-resistant major depressive disorder (MDD) (NCT00854100). The prima...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int Clin Psychopharmacol
Päätekijät: Fava, Maurizio, Durgam, Suresh, Earley, Willie, Lu, Kaifeng, Hayes, Robert, Laszlovszky, István, Németh, György
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams And Wilkins 2018
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6166709/
https://ncbi.nlm.nih.gov/pubmed/30045066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000235
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia